e-learning
resources
Copenhagen 2005
Tuesday 20.09.2005
Pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical and hemodynamic long term efficacy of sildenafil in primary pulmonary hypertension
J. B. Thorens, J. Plojoux, J. D. Aubert (Geneva, Lausanne, Switzerland)
Source:
Annual Congress 2005 - Pulmonary hypertension
Session:
Pulmonary hypertension
Session type:
Thematic Poster Session
Number:
3618
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. B. Thorens, J. Plojoux, J. D. Aubert (Geneva, Lausanne, Switzerland). Clinical and hemodynamic long term efficacy of sildenafil in primary pulmonary hypertension. Eur Respir J 2005; 26: Suppl. 49, 3618
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Long term benefit of sildenafil in patients with pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary circulation II
Year: 2009
Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension
Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Year: 2014
Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary circulation
Year: 2007
Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 347s
Year: 2007
Pulmonary arterial hypertension: Long term effects of oral ambrisentan on clinical status, exercise capacity and haemodynamics
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment
Year: 2012
Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 205s
Year: 2005
Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 598s
Year: 2002
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study
Source: Annual Congress 2010 - Pulmonary hypertension updates
Year: 2010
Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study
Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Year: 2011
Hemodynamical effects of metformin and sildenafil in the treatment of experimental pulmonary hypertension
Source: International Congress 2019 – Pulmonary hypertension: clinical
Year: 2019
Long term use of imatinib in patients with severe pulmonary arterial hypertension
Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension
Year: 2010
Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension
Source: Eur Respir J 2010; 36: 808-818
Year: 2010
Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012
Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Efficacy of epoprostenol treatment for pulmonary hypertension:
hemodynamic and clinical improvement during the initial 8-month period
Source: Eur Respir J 2001; 18: Suppl. 33, 325s
Year: 2001
Long term effects of transitioning from sitaxsentan to ambrisentan in pulmonary arterial hypertension
Source: Annual Congress 2010 - Pulmonary circulation III
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept